	Beneficio Bruto En Ventas		Fecha
Acadia Pharmaceuticals	USD 257.76M	778K	2025-12
Agios Pharmaceuticals	USD 18.09M	6.89M	2025-12
Alnylam Pharmaceuticals	USD 829.31M	219.56M	2025-12
Amarin	USD 22.21M	28.15M	2025-09
Amgen	USD 6.48B	307M	2025-09
Baxter International	USD 577M	373M	2025-12
Cara Therapeutics	USD 2.57M	1.11M	2025-03
Cytokinetics	USD 17.76M	15.82M	2025-12
DBV Technologies	USD 2.77M	33.21M	2025-09
Eli Lilly	USD 14.59B	1.48B	2025-09
Esperion Therapeutics	USD -29.52M	32.4M	2024-09
Halozyme Therapeutics	USD 281.77M	2.41M	2025-09
Intrexon	USD -297K	167K	2024-06
Ionis Pharmaceuticals	USD 195M	40M	2025-12
MannKind	USD 78.31M	76.21M	2025-12
Minerva Neurosciences	-4.27M	26.79M	2024-12
Nektar Therapeutics	USD 13.75M	650K	2024-06
Pfizer	USD 3.54B	7.61B	2025-09
Rigel Pharmaceuticals	USD 28.49M	7.01M	2024-06
United Therapeutics	USD 315.5M	286.6M	2025-12
Vanda Pharmaceuticals	USD 50.6M	5.5M	2024-12

Halozyme Therapeutics Beneficio Bruto En Ventas - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - Mar 2026.